Emerging therapeutic strategies to enhance HDL function

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Pharmacology

Background:

• Epidemiologic studies reveal a significant inverse correlation between plasma high-density lipoprotein (HDL) levels and cardiovascular disease (CVD) risk.
• High-density lipoproteins (HDL) are crucial for cardioprotection, primarily through the mechanism of reverse cholesterol transport (RCT).
• Recent advancements in understanding HDL biology and RCT have paved the way for developing novel therapeutic agents.

Purpose of the Study:

• To explore the potential of agents designed to enhance HDL function.
• To investigate the role of new therapies in promoting atherosclerosis regression.
• To highlight promising therapeutic strategies for cardiovascular disease treatment.

Main Methods:

• Review of epidemiologic data linking HDL levels to CVD.
• Analysis of the biological mechanisms of HDL-mediated reverse cholesterol transport (RCT).
• Evaluation of emerging therapeutic agents, including apo-AI analogs and CETP inhibitors (dalcetrapib, anacetrapib).

Main Results:

• Strong evidence supports an inverse relationship between HDL plasma levels and CVD incidence.
• Reverse cholesterol transport (RCT) is identified as a key cardioprotective pathway mediated by HDL.
• Apo-AI analogs and CETP inhibitors like dalcetrapib and anacetrapib show promise in increasing HDL function and potentially regressing atherosclerosis.

Conclusions:

• Novel agents targeting HDL function and RCT represent a promising frontier in cardiovascular disease management.
• Therapeutic strategies aimed at enhancing HDL functionality hold significant potential for atherosclerosis regression.
• Further research into apo-AI analogs and CETP inhibitors is warranted for their clinical application in CVD treatment.